Luna LifeSci Advisors
Luna LifeSci Advisors consults across the NAMs ecosystem, helping MPS developers grow and scale novel platforms, and guiding pharma and CROs to evaluate, adopt, and integrate MPS technologies into preclinical workflows. Our 25+ years of expertise spans strategy, technology development, platform validation, workflow integration, regulatory alignment, fundraising, company building, and commercial execution.
Nagi Bioscience
We are a Swiss high-tech company developing and offering cutting-edge biological testing solutions that enable scientists to generate insights they need to fuel life-changing discoveries in a faster, more efficient, and ethical way. Our technologies are designed to integrate seamlessly into existing lab environments, enhancing efficiency, accuracy, and reproducibility.
Optics11
Optics11Life develops cutting-edge life science tools using optical fiber sensing technology. The two main products are: The Nanoindentation Platform (Pavone, Piuma and Chiaro) and The Cuore 3D Engineered Muscle Contractility Platform
Ncardia
For more than a decade, Ncardia has been pioneering innovations in human induced pluripotent stem cells (iPSC).
NETRI
NETRI is an industrial start-up developing innovative technologies for the pharmaceutical industry. Its patented organs-on-chip technologies allow the creation of standardized and predictive human in vitro models.
Hesperos Inc.
Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.
Curi Bio
Curi’s suite of human iPSC-derived products and services enable scientists to build more mature and predictive human iPSC-derived tissues—with a focus on cardiac, musculoskeletal, and neuromuscular models—for the discovery, safety testing, and efficacy testing of new drugs in development.
MIMETAS
Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.